Back to dashboard
CommercialCoverageHigh impact

Cardiac Computed Tomography (CCT)/Coronary Computed Tomographic Angiography (CCTA) 6.01.34

Excellus BlueCross BlueShield·NY · Cardiology, Cardiothoracic Surgery, Radiology +3 more·Radiology (x-rays) & Imaging
Effective date
May 15, 2026
We identified it
Jul 16, 2026
Days to comply

Summary

Excellus BlueCross BlueShield has issued a comprehensive new policy (6.01.34) effective May 15, 2026, establishing detailed medical necessity criteria for Cardiac Computed Tomography (CCT) and Coronary Computed Tomographic Angiography (CCTA) procedures. The policy expands covered indications across multiple cardiac scenarios including chest pain evaluation, anomalous coronary artery assessment, pre-transplant evaluation, and structural heart disease assessment, while also establishing new requirements for FFR-CT and coronary plaque quantification.

Action Required

Action needed
By May 15, 2026: Billing and clinical teams must implement this new policy immediately upon effective date. REQUIREMENTS: (1) Providers must update order entry systems and clinical documentation templates to align with the 14 specific covered indications (A-Q) for CCTA outlined in Section I of the policy; (2) Billing team must establish prior authorization procedures to verify medical necessity against these criteria before claim submission; (3) Implement denial prevention by training front desk and clinical staff on the expanded covered scenarios, particularly new provisions for patients under 40 with suspected anomalous coronary arteries and pre-transplant cardiac evaluations; (4) Update claim review procedures to recognize FFR-CT as appropriate for uncertain physiologic significance on prior CCTA (Section II); (5) Configure billing system to require specific clinical documentation for coronary plaque quantification claims to meet the 'intermediate risk' or 'CAD-RADS 1-3' criteria in Section III; (6) Establish denial prevention rules rejecting plaque quantification claims within 30 days of MI or for unstable syndromes (Section IV); (7) Document all CCTA requests with specific clinical indicators from the policy to support medical necessity and prevent denials; (8) Train providers to understand distinction between covered plaque analysis scenarios (intermediate findings) versus non-covered scenarios (normal, high-grade stenosis, or CAD-RADS 0, 4, 5). Claims submitted without alignment to these specific criteria will be subject to denial.